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Schizophrenia: do all roads lead to dopamine or is this
where they start? Evidence from two epidemiologically
informed developmental rodent models
D Eyles
1,2, J Feldon
3 and U Meyer
3,4
The idea that there is some sort of abnormality in dopamine (DA) signalling is one of the more enduring hypotheses in
schizophrenia research. Opinion leaders have published recent perspectives on the aetiology of this disorder with provocative
titles such as ‘Risk factors for schizophrenia—all roads lead to dopamine’ or ‘The dopamine hypothesis of schizophrenia—the
ﬁnal common pathway’. Perhaps, the other most enduring idea about schizophrenia is that it is a neurodevelopmental disorder.
Those of us that model schizophrenia developmental risk-factor epidemiology in animals in an attempt to understand how this
may translate to abnormal brain function have consistently shown that as adults these animals display behavioural, cognitive
and pharmacological abnormalities consistent with aberrant DA signalling. The burning question remains how can in utero
exposure to speciﬁc (environmental) insults induce persistent abnormalities in DA signalling in the adult? In this review, we
summarizeconvergentevidencefromtwowell-describeddevelopmentalanimalmodels,namelymaternalimmuneactivationand
developmental vitamin D deﬁciency that begin to address this question. The adult offspring resulting from these two models
consistently reveal locomotor abnormalities in response to DA-releasing or -blocking drugs. Additionally, as adults these
animals have DA-related attentional and/or sensorimotor gating deﬁcits. These ﬁndings are consistent with many other
developmental animal models. However, the authors of this perspective have recently refocused their attention on very early
aspectsofDAontogenyanddescribereductionsingenesthatinduceorspecifydopaminergicphenotypeintheembryonicbrain
and early changes in DA turnover suggesting that the origins of these behavioural abnormalities in adults may be traced to early
alterations in DA ontogeny. Whether the convergent ﬁndings from these two models can be extended to other developmental
animal models for this disease is at present unknown as such early brain alterations are rarely examined. Although it is
premature to conclude that such mechanisms could be operating in other developmental animal models for schizophrenia, our
convergent data have led us to propose that rather than all roads leading to DA, perhaps, this may be where they start.
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Introduction
That schizophrenia is considered a disorder of brain devel-
opment is now no longer a matter of debate. Although
symptom onset is in early adulthood, convergent evidence
from the ﬁelds of epidemiology, neuroimaging and post-
mortem analysis strongly suggest that disruptions to early
brain development are causal.
1,2 However, the diverse array
of adverse gestational events that have been associated with
schizophrenia such as fetal hypoxia, obstetric complications,
maternal infection/immune function, season of birth and
maternal stress hampers the search for a common aetiology.
3
The situation regarding the contribution of individual genes to
schizophrenia is no less clear with at last count no fewer than
43 candidates having been proposed.
4,5 Although polymorph-
ismswithinenzymesinvolvedindopamine(DA)turnoversuch
as mono-amine oxidase A and catechol-o-methyl transferase
or DA 2 and 3 receptors rank highly among such candidates,
none are signiﬁcantly altered at the genome-wide level.
5
However, the ﬁnding within the most recent Genome-Wide
Association Study that patients may have alterations in a
regulatory micro-RNA element for genes that control neuronal
development may represent a real step forward in such
studies.
6
Although abnormalities in most neurotransmitter systems
have been linked with this disorder, alterations in DA
neurotransmission remain central to both its treatment and
aetiological understanding.
7 Hypotheses linking abnormal
Received 26 October 2011; revised 13 December 2011; accepted 8 January 2012
1Queensland Brain Institute, University of Queensland, Brisbane, Queensland, Australia;
2Queensland Centre for Mental Health Research, The Park Centre for Mental
Health, Wacol, Queensland, Australia;
3Laboratory of Behavioural Neurobiology, Swiss Federal Institute of Technology Zurich (ETH), Schwerzenbach, Switzerland and
4Physiology and Behaviour Laboratory, Swiss Federal Institute of Technology (ETH) Zurich, Schwerzenbach, Switzerland
Correspondence: Dr D Eyles, Queensland Centre for Mental Health Research, Queensland Brain Institute, University of Queensland, St Lucia, Brisbane, QLD 4072
Australia.
E-mail: eyles@uq.edu.au; web address: www.qcmhr.uq.edu.au or www.qbi.uq.edu.au
Keywords: brain development; dopamine; maternal immune activation; ontogeny; schizophrenia; vitamin D
Citation: Transl Psychiatry (2012) 2, e81, doi:10.1038/tp.2012.6
& 2012 Macmillan Publishers Limited All rights reserved 2158-3188/12
www.nature.com/tpdopaminergic function and schizophrenia date from the
seminal work of Carlsson and Lindquvist.
8 Not surprisingly,
in 50 years this hypothesis has been modiﬁed. The initial
postulate that schizophrenia was a disorder of excess DA
activity underwent a major revision in the early 1990s that
attempted to incorporate positron emission tomography data
that suggested there was hypofrontality in cortical regions.
The proposal, bolstered by studies in animals, was that this
hypofrontality was due to abnormally low dopaminergic
signalling in cortical regions.
9 This suggestion received direct
supportfromthepositronemissiontomographystudiesofAbi-
Dargham et al.
10 who showed that DA (D1) receptors were
increased in the dorso-lateral prefrontal cortex of patients with
schizophrenia.ThiselevationintheprimaryDAreceptorinthe
cortex correlated strongly with working memory deﬁcits in
these patients. Positron emission tomography studies, how-
ever, have provided a much more robust evidence base to
support the original proposal that patients with schizophrenia
have excessive subcortical dopaminergic activity with
increased DA release, synthesis and storage.
11–16
A common perspective that has emerged over the past few
years is that DA abnormalities may represent an end state for
multiple environmental and genetic factors that operate in
unison to predispose an ‘at risk’ individual to symptomatic
onset. This concept has been summarized in recent reviews
with titles such as ‘Schizophrenia: from developmental
deviance to DA dysregulation’,
17 or ‘Risk factors for schizo-
phrenia—all roads lead to DA’.
18 Perhaps even more
succinctly, DA abnormalities in schizophrenia have been
referred to as the so-called ‘Final Common Pathway’ or
versionIIIofthehypothesis.
19Althoughsuchperspectivesare
parsimonious in attempting to draw together the widely
disparate data concerning the various risk factors and genes
that contribute to this disorder, there is still the need to
integrate dysfunctional DA signalling in the adult patient with
the epidemiology indicating schizophrenia is a disorder of
early brain development.
It is important here to consider the consequences of
interfering with DA signalling during fetal brain development.
Maternal use of agents that increase extrasynaptic DA such
as cocaine or amphetamine can induce deﬁcits in cognitive
and attentional systems in children.
20 Neuroimaging studies
on such children also suggest these agents can alter DA
receptor and transporter numbers and produce reductions in
the volumes of major dopaminergic terminal ﬁelds like the
striatum.
21,22 It would be of intense interest to follow-up
psychiatric outcomes in such children.
An examination of the so-called ‘prodromal stage’ of the
disease also provides evidence for underlying dopaminergic
deﬁcits in schizophrenia. In an important recent study, adults
that were at risk but asymptomatic who later progressed to
psychosis were shown to have increased subcortical DA
uptake compared with controls, indicating dysfunction in DA
signalling may be a precursor to schizophrenia.
23
The obstacles to unravelling the shared mechanisms
between the diverse genetic and environmental factors
responsible for schizophrenia are considerable. First, there
is no single exposure/gene variant or early diagnostic feature
predictive for later onset of this disease. Second, the ability to
study brain development in humans is obviously fraught with
technical difﬁculties. Finally, even if the research community
could agree on the worthiness of any early candidate
exposure/s, such a research programme would need to be
followed up for decades to correlate early life exposure with
onset of symptoms, a course that is clearly not practical.
The use of neurodevelopmental animal models drastically
reduces these ethical and temporal demands.
24 Of the
plethoraofmodelshavebeendeveloped(primarilyinrodents)
one feature that would appear to be germane would be an
alteration of DA-related behaviours in the adult. Manyof these
models possess strong face and/or predictive validity for the
disorder.
25 In particular, prenatal exposure to the DNA
methylation agent methylazoxymethanol acetate, and the
postnatal ventral hippocampal lesion model produce adult
animals that perhaps best phenocopy certain aspects of
abnormal brain function in patients.
26,27 Such phenotypes are
attenuated by antipsychotics indicating these models also
possessstrong predictivevalidity. These models are now also
providing some mechanistic understanding behind how
developmental interventions can induce loss of cortical
GABAergic interneuron function, a particularly prominent
explanation for higher cortical dysfunction in schizophrenia.
28
The work of O’Donnell
29 and others is particularly important
here as this group has shown that neonatal hippocampal
lesions impair dopaminergic innervation of the prefrontal
cortex during adolescence. This is therefore direct evidence
that an early postnatal intervention that is believed relevant to
schizophrenia can induce late (adolescence) developmental
alterations in DA ontogeny. The perinatal hypoxia models
designed to examine the effects of obstetric complications
also produce abnormalities in offspring behaviour that
implicate impaired DA signalling.
30
Other models have even directly modiﬁed postnatal DA
signalling via early transient alterations in D2 receptor
density
31 or indirectly by exposing maternal animals to DA-
releasing agents such as amphetamine.
32 Not surprisingly,
such exposures produce long-lasting changes in DA-related
behaviours in the exposed offspring. An excellent register
of all such models was prepared by Koenig et al. and is
freely available http://www.schizophreniaforum.org/res/models/
default.asp.
Although such models are informative regarding the effect
ofearlyenvironmentonbraindevelopmentandfunctionasyet
they tell us little about how such adverse exposures could
interact with genomic factors. Additionally, as useful as many
of these models are for understanding the abnormal con-
nectivity and brain function that may result from adverse
developmental exposures, many of them, that is, neonatal
ventral hippocampal lesion or prenatal methylazoxymethanol
acetate exposure have no direct aetiological relationship with
schizophrenia as patients have not been exposed to severe
mitogens during development or have lesions within their
hippocampus. The three authors of this current review have
over the past 10 years been primarily responsible for the
development of the developmental vitamin D (DVD)-deﬁ-
ciency and maternal immune activation (MIA) models, which
are both featured in the aforementioned register. These
models share both the face and predictive validity of many
other developmental animal models but are based on
epidemiologically proven risk factors. Independently, we have
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whether these exposures could produce any early neurobio-
logical alterations. Our unique contribution to the ﬁeld is the
realization that these models show very early changes in the
expression of genes that are either involved in the induction
and/or speciﬁcation of DA neurons or in the expression of
enzymes responsible for DA turnover. We hypothesize that
such early alterations subtly alter the ontogeny of DA neurons
creating long-lasting changes in DA neuron connectivity,
function and perhaps even survival. We consider it highly
plausible that very early alterations in DA-mediated pathways
may be induced in other developmental models for this
disorder. Appropriately, the authors of animal models for
schizophrenia have focused on replicating as much of the
structuralandbehaviouralphenotypeintheadultoffspring(for
an excellent recent summary, see Brown
33). However, most
authors have completely ignored the developing brain in such
studies at any time point proximal to the adverse maternal or
postnatal exposure. Therefore, there is an absence of data
concerning early aspects of DA or any other neurotransmitter
ontogeny in such models. Our choice therefore to focus on
dataobtainedfromtheDVD-deﬁciencyandMIAmodelsinthis
review is due to an absence of published evidence in other
animal models. We think it entirely likely that early aspects of
DA ontogeny may also be altered in other models. We believe
that future studies directed toward understanding what
common early mechanism/s underpin DA neuron dysfunction
intheadultmayrepresenta usefulapproachtounderstanding
the aetiology of this disease.
The DVD-deﬁciency and MIA developmental animal
models of schizophrenia
DVD-deﬁciency has been shown to be a direct risk factor for
schizophrenia with an odds ratio of 2.0.
34 There is also some
indirect supporting evidence.
35,36 The proposal that maternal
vitamin D deﬁciency could be a risk-modifying agent for
schizophrenia was made 11 years ago.
37 This led to the
development of a rodent model restricting the period of
vitamin D deﬁciency to gestation.
38 This model describes
structural brain changes such as ventriculomegaly,
38,39
baseline cognitive abnormalities in domains of attention
40
and behavioural sensitivity to both N-methyl-D-aspartate
antagonists and amphetamine,
41–43 meaning this model
possesses strong face and construct validity. Although the
predictivevalidityofthismodelhasbeenlesswellestablished,
it has been explored in some detail by one group. In their ﬁrst
study, this group showed that haloperidol, a widely prescribed
antipsychotic, could restore habituation deﬁcits in an explora-
tion paradigm.
44 Next, this group demonstrated that DVD-
deﬁciency altered hippocampal long-term potentiation, a
neurobiological correlate of learning and memory. They
showed that both risperidone and haloperidol normalized
long-term potentiation in DVD-deﬁcient offspring.
45 Most
recently, this group showed that haloperidol restored adult
neurogenesis deﬁcits in this model.
46 Studies in other
laboratories have also shown that haloperidol appeared to
preferentially normalize N-methyl-D-aspartate antagonist
induced hyperlocomotion in DVD-deﬁcient rats compared
with that induced in controls.
41
MIA or prenatal exposure to infection are also well-
established risk factors for schizophrenia.
47,48 The relative
oddsriskofMIAinducedbyavarietyofprenatalinfectionshas
been summarized in a recent review as being between 2–6
and 3.0 depending on the nature and timing of the infection.
48
Animal models have been developed to explore the
underlying neurobiology of this risk.
49 One such MIA model
makes use of prenatal maternal treatment with the viral
mimic polyriboinosinic-polyribocytidilic acid (poly(I:C)), a
synthetic analogue of double-stranded RNA that readily
stimulates cytokine-associated viral-like acute phase
responses in maternal and fetal compartments. A plethora
of experimental studies have revealed that prenatal poly(I:C)
treatment in mid-gestation (in mice typically Bgestation day
9 to 12; in rats typically Bgestation day 15) leads to the
emergence of multiple behavioural, cognitive and pharma-
cological dysfunctions in adulthood, many of which are
directly implicated in schizophrenia (reviewed in Meyer and
Feldon
24). The spectrum of such dysfunctions includes
abnormalities in sensorimotor gating, selective attention,
social interaction, working memory and sensitivity to psy-
chostimulant drugs. Many of the prenatal poly(I:C)-induced
functional abnormalities can be normalized by acute and/or
chronic antipsychotic drug treatment and are dependent on
post-pubertal maturational processes.
50–55 The functional
brain alterations in this MIA model are accompanied by a
wide spectrum of neuroanatomical and neurotransmitter
changes in the adult central nervous system, some of which
are again highly relevant for schizophrenia, including
presence of enlarged lateral ventricles,
56,57 reduced hippo-
campal and prefrontal cortical expression of Parvalbumin
and Reelin,
58 and numerous DA abnormalities representa-
tiveof an overactivestriatal DA system.
51–54 Taken together,
the poly(I:C)-based MIA model in rats and mice is character-
ized by a high level of face, construct and predictive validity
for schizophrenia-like pathology.
DVD-deﬁciency and MIA have also been implicated as risk
factors for other psychiatric disorders such as autism. The
evidence for DVD-deﬁciency, however, is at best indirect
59
and often absent.
60,61 Large cross-sectional association
studies are still yet to be published. The evidence for MIA is
slightly stronger. Children who develop autism have abnorm-
alities in peripheral immune function
62 and poly(I:C)-exposed
mice develop abnormalities in cerebellar Purkinje cells similar
to that seen in children with autism.
63
DVD-deﬁciency and DA dysfunction in adult offspring
Early studies reported that rat weanlings deprived of dietary
vitamin D had increased catecholamine levels in cortical and
hypothalamic areas when examined as adults.
64 A laterstudy
in vitamin D-deﬁcient animals also provided some support for
increased DA levels in striatum.
65 However, unlike DVD-
deﬁcient rats, co-existing hypocalcaemia in both these early
studies may confound any direct effect of vitamin D
deﬁciency. Curiously, DA can also induce signalling at the
vitamin D receptor in the absence of the vitamin, suggesting a
complex interaction between vitamin D and catechola-
mines.
66 Indirect indications that vitamin D may affect
dopaminergic signalling also come from the recognition that
DA ontogeny and schizophrenia
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synthesis of the active form of the hormone CYP27B1 have a
strong distribution in the DA-rich region of the human brain,
the substantia nigra.
67
Spontaneous hyperlocomotion in response to a novel
environment is a common behavioural readout of an under-
lying hyperdopaminergia. When DVD-deﬁcient rats are
placed in a novel arena these animals display spontaneous
hyperlocomotion without any anxiety or depressive-like
phenotype.
68 This is unlikely to be a stress-mediated
mechanism because the animals have normal hypothalamic
pituitary adrenal axis-mediated stress responses.
69 These
animals are also selectively sensitive to the locomotor-
enhancing effects of amphetamine, a drug that enhances
DArelease.
43ArelationshipbetweenvitaminDandDAinvivo
is further supported via experiments where the active form of
vitamin D, 1,25(OH)2D3 is given to adult animals. When
1,25(OH)2D3 is administered long-term, increased basal
striatal DA levels and increases in evoked release of DA
result.
70 1,25(OH)2D3 has also been administered to newborn
rats and DA and noradrenalin measured in a variety of brain
regions in these animals as adults. These studies revealed
that DA and noradrenalin were elevated mainly in the
brainstem of these animals as adults.
71
MIA and DA dysfunction in adult offspring
Prenatal immunological insults using agents such as poly(I:C)
are capable of inducing long-lasting molecular and functional
brain abnormalities in the adult, which are strongly associated
with imbalances in the mesolimbic and/or mesocortical DA
system.
72 One of the well-established functional phenotypes
displayed by adult poly(I:C) offspring is the potentiation of
amphetamine sensitivity.
51,53,54 Furthermore, adult offspring
born to poly(I:C)-treated mothers show a DA-dependent
disruption of selective attention and sensorimotor gating.
Accordingly, DA receptor-blocking compounds can effectively
normalize such deﬁcits in adult poly(I:C) offspring.
53–55 There
is also robust evidence for the presence of long-term DA-
related molecular alterations in the adult central nervous
system of prenatally poly(I:C)-treated animals. First, similar to
post-mortem ﬁndings in schizophrenic patients,
73 these
animals consistently show enhanced striatal expression of
tyrosine hydroxylase (TH), the rate-limiting enzyme in the
biosynthesis of DA.
51,54 Importantly, the implementation of
neonatal cross-fostering procedures in the mouse poly(I:C)
MIA model suggests that the effects of prenatal immune
activation on altered striatal TH expression are attributable to
prenatal but not postnatal maternal effects on the offspring.
This is evidenced by enhanced striatal TH immunoreactivity
being found in prenatally poly(I:C)-treated offspring regard-
less of whether they were raised by surrogate dams, which
had experienced poly(I:C) treatment during pregnancy, or
whethertheywereadoptedbysham-treatedcontrolsurrogate
dams.
51 In addition to presynaptic dopaminergic changes,
adultpoly(I:C)offspringhavealsobeenreportedtodisplayDA
receptor changes relevant to schizophrenia, including re-
duced densities of D1 receptors in prefrontal cortex and
elevated densities of D2 receptors in the striatum.
51,54 Finally,
increased basal levels of the DA metabolite homovanillic acid
and enhanced KCl-induced DA release have been reported in
striatal regions of adult poly(I:C)-exposed animals.
53,74
Many of these DA-related molecular and behavioural
abnormalities have also been reported in adult offspring from
other developmental animal models for schizophrenia.
75
However, new data from both the DVD-deﬁciency and MIA
models are now indicating that there may be very early
alterations in dopaminergic components in both these
models.
DVD-deﬁciency and DA ontogeny
DVD-deﬁciency alters factors important in the ontogeny of
embryonic rat dopaminergic neurons. The vitamin D receptor
initially appears in the developing brain on embryonic day 12
(E12), where it is most highly expressed in the neuroepithe-
lium of the midbrain.
76 Almost all mesencephalic DA (msDA)
neurons are born between E11 and E14 in the Sprague–
Dawley rat, with 80% of these cells being born between E11
and E12.
77 E12 therefore potentially represents a critical time
for the convergence between vitamin D function in embryonic
brain and DA ontogeny. To examine this link, a recent study
examined DA-selective gene expression in embryonic me-
sencephalon at two speciﬁc ages, E12 representing the peak
formsDAneuron proliferation, and E15,a developmentaltime
point representing a largely post-proliferation period for msDA
neurons.
77 The most widely studied early speciﬁcation factors
for msDA neurons, (Nurr1, p57Kip2, Lmx1b and ptx3) were
investigated.
78 TH expression was also quantiﬁed at these
time points as a marker of dopaminergic phenotype. This
study revealed that the crucial speciﬁcation factor for
dopaminergic phenotype Nurr 1 (also known as NR4A2 an
orphan nuclear receptor) was reduced at E12 in the
mesencephalon of DVD-deﬁcient rat embryos. A co-related
factor, p57Kip2, was also reduced at this age. At the later
embryonic age, E15, Nurr 1 expression was still reduced but
p57Kip2 levels had normalized. Early markers for dopami-
nergic maturation such as TH, also appeared to be reduced
especially at the earlier age.
79
DA levels have also been examined directly in the neonatal
forebrains of DVD-deﬁcient neonates. Although DA levels
were shown to be normal, its metabolism was altered with
increased ratios of 3,4-dihydroxyphenylacetic acid/homova-
nilic acid (two major DA metabolites).
80 This was accompa-
nied by a reduction in catechol-o-methyl transferase, the
enzyme that converts 3,4-dihydroxyphenylacetic acid to
homovanilic acid. Therefore, it would appear that in a
normo-calcaemic environment vitamin D deﬁciency may not
affect DA levels in developing brains per se but may affect its
turnover.
MIA and DA ontogeny
Changes in speciﬁcation and induction factors speciﬁc for DA
neurons have also been reported in the whole brains of
embryos derived from gestational day 9 poly(I:C)-exposed
mice. It is important to emphasize that a single maternal
poly(I:C) administration regime induces a marked but highly
time-limited inﬂammatory response in the maternal host,
lasting only approximately 36–48h.
49 A strength of the
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meaningtheadverseeffectsofinﬂammationcanbestudiedat
discrete gestational ages. In the ﬁrst study that examined the
effects of MIA on DA ontogeny, embryos were examined 2, 4
and8 days after poly(I:C) exposure.The ﬁrst period examined
wasE11,whichapproximatesthepeaktimeforDAcell birthin
the mouse.
81 The later periods E13 and E17 reﬂect an
immediate and a more distal post-mitotic stage for DA
neuronsinthemouse.
82Thisinitialstudydescribedacomplex
dynamic relationship between early inductive factors such as
Sonic hedge hog and ﬁbroblast growth factor 8 (fgf 8), which
were expressed at control or even elevated levels at E11
gradually reducing to below control levels by E17.
83 This
correlated inversely with an initial decrease in the expression
of the important dopaminergic speciﬁcation factors Nurr 1 and
ptx 3 at E11 a ﬁnding that had normalized by the ﬁrst post-
mitotic stage for DA neurons, E13.
It is interesting to note that at later embryonic stages such
asE17andE19,whenmsDAneuronsarelargelypost-mitotic,
embryos derived from poly(I:C)-exposed mice show a
signiﬁcant increase in the number of TH- and Nurr1-positive
cells.
54,83 Thus, it appears that subsequent to the initial
decrease at early-to-mid embryonic stages, early gestational
immune challenge induces an over compensation in the
expression of speciﬁcation and maturational dopaminergic
markersat later stagesof development. Therefore, the effects
of MIA on dopaminergic systems are not static. Rather, these
early-life insults induce primary changes in early embryonic
DA development, which then interact with maturational
processes to precipitate long-term dopaminergic abnormal-
ities that are, at least in part, dependent on the actual stage of
pre- and postnatal development.
DVD-deﬁciency and MIA, early effects on DA ontogeny
Taken together, there are some coherent patterns emerging
within the DVD-deﬁciency and poly(I:C) models as regards to
their effects at least on early phases of DA ontogeny. In both
the DVD-deﬁcient rat and the prenatal poly(I:C)-exposed
mouse, there is an initial reduction in expression of factors
crucial for specifying dopaminergic phenotype at times
reﬂecting the peak period of DA cell birth in both species,
E12andE11,respectively.ThisabnormalityinDAontogenyis
normalized somewhat when next examined at a period
representing a largely post-mitotic phase for dopaminergic
neurons. This correction is complete for Nurr 1 and ptx3 in the
poly(I:C) model and partial for the DVD-deﬁciency model with
p57Kip2 expression returning to control levels but Nurr 1
expression remaining reduced at E15. Later embryonic
stages indicate that Nurr 1even appears to be increased in
the poly(I:C)-exposed brains. Such stages in embryonic
mesencephalic development have yet to be examined in the
DVD-deﬁcient embryos.
Is there evidence for a direct mechanism? Despite the
collective data presented that suggests both models alter
factors important in DA ontogeny, evidence for a direct
mechanism is still lacking. Direct links have been made
between vitamin D enhancing the production of TH both in
vitro
84 and in certain in vivo pathological models.
85–87
Vitamin D may also increase TH indirectly by promoting
glial-derived neurotrophic factor production.
88 Glial-derived
neurotrophic factor activates TH by phosphorylating this
enzyme in DA-rich brain regions.
89 The developmental
absence of vitamin D therefore is consistent with a
reduction in TH in utero
79 but evidence for a direct
mechanism is still lacking.
Poly(I:C) releases a cascade of pro-inﬂammatory cyto-
kines, which are likely to cross the placenta and inﬁltrate the
developing brain.
90 Cytokines released after poly(I:C) ex-
posure include the pro-inﬂammatory cytokine interleukin-1b,
which is known to exert multiple direct effects on DA
development and/or maturation, including promotion of DA
phenotypes in mesencephalic progenitor cells
91–93 and
enhancement of fetal DA cell survival.
94 Mitotic progenitor
cells isolated from the embryonic rat mesencephalon are also
known to potently respond to a combination of interleukin-1,
interleukin-11, leukaemia inhibitory factor and glial-derived
neurotrophic factor promoting cells toward a dopaminergic
phenotype.
93 A cytokine-enhanced survival of dopaminergic
cell types would appear to contrast with the initial reduction in
markersfordopaminergicphenotypeseeninpoly(I:C)-treated
embryos. However, with regards to direct cytokine effects on
DA development, it is important to emphasize that the
responsiveness and/or sensitivity of developing cells to (pro-
inﬂammatory) cytokines can vary considerably with neurode-
velopmentalstage.
95Forexample,whilethepro-inﬂammatory
cytokine tumour necrosis factor-a is neurotrophic to dopami-
nergic ventral mesencephalic neurons during early fetal
development, the same molecule can exert neurotoxic effects
on these cells at later stages of fetal brain development.
96,97
Therefore, while it remains entirely plausible that poly(I:C)-
induced alterations in inﬂammatory cytokines may be respon-
sible for early alterations in DA ontogeny, the timing of such
alterations must be strictly observed before a direct mechan-
ism could be postulated.
Evidence for an indirect mechanism. T h ea l t e r a t i o ni nt h e
temporal pattern of DA-related gene expression in both models
is highly suggestive that they may occur secondary to a delay
in DA neuron maturation. Such a proposal is consistent with
both the knowledge that vitamin D is a critical differentiation
factor in numerous cell types;
98 and the observation that
cytokine-associated inﬂammatory events in the early fetal brain
primarily affect cell proliferation and differentiation.
99
If vitamin D is removed during development, cell prolifera-
tion is enhanced across most brain regions
38,100 with
corresponding changes in cell-cycle and apoptotic gene
expression.
100 Progenitor cell formation is also enhanced in
these brains.
101 This ﬁnding can also be reversed via the
addition of 1,25(OH)2D3.
101 Additionally, adding 1,25(OH)2D3
to primary hippocampal cells in culture differentiates them by
decreasing the number of proliferating cells and increasing
neurite outgrowth.
102 On the balance of this evidence,
therefore, it would appear that DVD-deﬁcient embryonic
brains are less differentiated. Given that embryonic DA cells
immediately begin to express Nurr1 only once progenitor cells
stop proliferating
103 and 8h later p57Kip2 (ref. 104)one would
predict that the expression of these factors would be delayed
or decreased in DVD-deﬁcient mesencephalon. The high
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phalon at E12 further suggests that this region could be
particularly sensitive to vitamin D status.
76
Similarly, in the poly(I:C) model an initial increase in the
expressionofinductionfactorssuchasfgf8atthepeakperiod
of DA neuron birth (E11 in the mouse) is suggestive of
enhanced proliferation and a delay in differentiation.
83 This
ﬁndingisinternally consistentwiththe initial decreaseor delay
intheexpressionofpost-mitoticfactorssuchasNurr1andptx
3 in these same mouse embryos. The normalization of Nurr 1
and ptx 3 expression in poly(I:C)-treated embryonic brains by
E13(alargelypost-mitoticstageforDAneuronsinthemouse)
correlates with a rapid decrease in the expression of both fgf 8
and Sonic hedge hog (another important induction gene for
DA neurons) indicating DA cells have ceased dividing.
82
Unfortunately,thesesameearlyinductionfactors havenotyet
been studied in the DVD-deﬁciency model. Nevertheless,
vitamin D3 is known to suppress the transcription of fgf 8.
105
Therefore, it is plausible that the expression of fgf 8 may also
be elevated in the DVD-deﬁcient brain.
Although a delay in the development of dopaminergic
systems have been reported here, we cannot rule out
alterations in the early maturation of other neurotransmitter
systemsinbothmodels.Forinstance,abnormalitiesinselective
aspects of GABA signalling have been reported to be altered in
adult offspring in both models.
39,106 However, it must be noted
that cortical GABAergic systems develop later than dopami-
nergic systems, therefore such changes may well occur
secondary to a primary developmental DA disruption. Addition-
ally, a study of neuroactive amines in DVD-deﬁcient neonatal
brains revealed that DA alone was altered when compared with
noradrenalin and serotonin.
80 Unfortunately, no similar studies
have been conducted in poly(I:C)-treated brains.
What are the consequences of altered DA ontogeny for
the developing brain?
Alterations in early induction factors such as fgf 8, Sonic
hedge hog; speciﬁcation factors for dopaminergic phenotype
such as Nurr 1, p57Kip2 and ptx3; and the reduction of
enzymes crucial for DA turnover such as catechol-o-methyl
transferase in the embryonic brain are likely to be highly
relevant for developing msDA neurons. Fgf 8 is secreted from
the rostral hindbrain early in development and is essential for
the orderly formation of the boundary between mid and hind-
brain.
107 In particular, it would appear that fgf 8 is essential for
theproperpositioningofmitoticcellswithinthisregionmanyof
which will become dopaminergic.
78 Nurr1 is an obligatory
factor in msDA neuron development and maturation.
108
Studies have convincingly shown that Nurr1–/– transgenic
animals have complete agenesis of DA neurons, whereas
other monoamine neurons such as serotonin and noradrena-
line are unaffected.
109 Nurr1 also has a number of functions in
post-mitotic and mature msDA neurons.
82,110 It regulates DA
synthesis via TH, vesicular content via the transporter
VMAT2, release via the DA transporter and trophic support
via regulation of the receptor for glial-derived neurotrophic
factor, c-RET.
78 The long-term consequences of Nurr 1
ablation cannot be studied in the homozygote as this deletion
is lethal, but in the heterozygote this leads to a reduction in
TH-positive neurons.
111
Nurr1 and p57kip2 expression appear to be closely linked.
82
p57kip2 is drastically reduced in Nurr1þ/– embryonic brains.
p57Kip2 co-immunoprecipitates with Nurr1 when Nurr1 anti-
bodies are used in disassociated rat mesencephalon.
103
Therefore, it would appear that Nurr1 and p57kip2 co-operate
to regulate DA cell differentiation and maturation. p57Kip2,
however, is also an important agent independent of Nurr 1 in DA
ontogeny. p57Kip2 null mutant mice have no TH-positive
mesencephalic cells at E18.5.
104 Although p57kip2 is a cyclin-
dependent kinase inhibitor and therefore likely to have some
effect on cell-cycle it would appear that at least in the embryonic
mesencephalon it is primarily involved in post-mitotic functions
suchascellmigrationandsurvival.
103,104Thegeneticablationof
either Nurr1 or p57Kip2 both lead to a preferential reduction in
lateral migration of msDA neurons,
103,108,110 that is, those
neurons most likely to form the embryonic substantia nigra.
Whether this affects cell number within the ventral tegmental
area is unknown. Additionally, the timing of cell division also
inﬂuences eventual cell positioning with neurons that cease
division early migrating most rostrally in the mesencephalon.
112
Thus, the combination of delayed differentiation and reduced
expression of factors such as p57Kip2 in DVD-deﬁcient
mesencephalon and Nurr 1 at least initially in both models could
likely lead to abnormal rostral/lateral migration of msDA neurons
with the downstream effects on dopaminergic connectivity.
ptx 3 is another speciﬁcation agent for DA neurons being
speciﬁcally involved in terminally differentiating DA neu-
rons.
113 ptx 3 acts co-operatively with Nurr 1 in post-mitotic
DA neurons to achieve this.
114 In the poly(I:C)-exposed
embryo, expression of ptx 3 mimicked that of Nurr 1. Finally,
alterations in enzymes such as catechol-o-methyl transferase
with concomitant alterations in DA turnover could also reﬂect
early changes in DA innervation and/or signalling. The
molecular alterations induced by DVD-deﬁciency or MIA in
factors involved in these early aspects of msDA neuron
ontogeny are summarized in Figure 1.
Taken together, the evidence obtained from both these
developmental models indicate that there are early alterations
in the expression of genes involved in the induction,
positioning and differentiation of dopaminergic neurons,
however, many questions remain. We know very little about
how such early alterations could affect DA cell maturation
processes in developing mesencephalon or how these
changes could lead to abnormal dopaminergic signalling in
the adult. Indeed, apart from a modest volume of literature
dealing with the long-term effects of reduced Nurr 1 (see
below), there are few studies that have examined adult brain
function inmodels of compromised dopaminergic ontogeny.
54
Moreover, apart from the transient D2 overexpressing mouse
(see below),
31 studies that examine adult brain function in
models where interventions are restricted to early critical
periods in DA ontogeny are conspicuous by their absence.
What are the consequences of altered DA ontogeny for
adult brain function?
Studies concentrating on the selective modulation of early
genes crucial in specifying dopaminergic phenotype and what
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be are in their infancy. One of the most well-studied factors to
date is Nurr 1. Adult Nurr1þ/  mice have (a) spontaneous
locomotion in response to novelty;
115–117 (b) enhanced
locomotion in response to both amphetamine
115,117 and
N-methyl-D-aspartate antagonists;
117 and (c) increased sen-
sitivity to the locomotor retarding properties of haloperidol.
117
This behavioural phenotype has led to the proposal that the
Nurr1þ/  mouse may be a viable animal model of schizo-
phrenia.
117 As previously discussed, this behavioural pheno-




51–55 A direct link between changes in these
maturation factors for DA neurons and schizophrenia has
also been made. A reduction in Nurr1 in the brains of patients
with schizophrenia has been described.
118 Polymorphisms in
ptx3and otherspeciﬁcation agentssuchasLMX1Bhave also
been reported in patients with schizophrenia.
119 Current
investigation of ptx 3 and brain function is hampered by the
fact that ptx3 transgenic mice do not respond to either DA
agonists or antagonists.
120
Although the use of transgenics in the study of schizophrenia
is common, there is far less work using mutant strains where
gene expression is conditional. Elucidating the ‘when and
where’ of gene expression, especially during neurodevelop-
ment will undoubtedly advance our understanding of the
complex mechanisms within schizophrenia. Unfortunately,
researchers interested in modelling the psychopathology of
diseases such as schizophrenia all too rarely investigate the
effects of transiently altering the expression of factors important
to the developing brain. The approach of Kellendonk et al.
31 is
probably best known here. This group generated mice that
expressincreasedlevelsofD2receptorsinaspatiallyrestricted
and temporally controlled manner. This group were able to
verify that prolonged alteration in DA signalling throughout
development and post-natal stages led to altered behaviours
even whenreceptor density was normalizedintheadult. Similar
inducible strategies have been tried with disrupted in schizo-
phrenia 1, reviewed in Pletnikov.
121
Generation of these models, however, is time consuming,
costly and currently restricted to single genes. The more
recent advent of RNA interference technology has allowed
investigators to achieve localreductions in gene expression in
discrete brain nuclei. This technology is only now being
applied to altering the expression of genes of intense interest
to schizophrenia researchers such as disrupted in schizo-
phrenia 1 (ref. 122) and D-amino acid oxidase.
123 Despite
these successes, the spatial and temporal control of gene
expression in the developing or adult rodent brain remains
technologically challenging.
These issues are drastically simpliﬁed in less complex
organisms.Forinstance,themanipulationofgene-expression
inthelarvalZebraFish(DanioReio)brainviaMorpholinoRNA
interference techniques is routine. Moreover, some groups
have already described persistent functional consequences
for DA-mediated behaviours in Zebra Fish in which Nurr 1
expression was reduced early in development.
124 Drosophila
melanogaster is even more accessible as a species for such
investigation. For instance, the insertion of disrupted in
schizophrenia 1 into Drosophila has recently been studied
as an animal model of schizophrenia.
125 Additionally, the
varietyoftechniquestoinduceorsilencegeneexpressionand
the strict temporal control of such gene-switching would
appear to only be limited by the investigators imagination. The
schizophrenia research community also would appear to be
now considering this approach.
126
Figure 1 A summary of factors involved in the induction, speciﬁcation and maturation of dopaminergic (DA) neurons affected by either developmental vitamin D (DVD)-
deﬁciency or maternal immune activation (MIA) at various stages of embryonic brain development. (m Increase in expression; . decrease in expression; ’ expression
normalized or unaltered). COMT, catechol-o-methyl transferase; DOPAC, 3,4-dihydroxyphenylacetic acid; FGF8, ﬁbroblast growth factor 8; HVA, homovanilic acid; SHH,
Sonic hedge hog; TH, tyrosine hydroxylase.
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deﬁciency and MIA be linked as risk factors for
schizophrenia?
There is clinical evidence to support the proposal that DVD-
deﬁciency and MIA represent independent risk-modifying
factors in schizophrenia. However, what may be less
appreciated is that there could be some interaction between
these non-genetic risk factors. There is now widespread
agreement that vitamin D is a potent immunosuppressant.
127
A number of studies have shown vitamin D to be a potent
suppressor of the types of inﬂammatory cytokines produced
by MIA. This has led to the exploration of vitamin D in certain
models of brain inﬂammation.
128 Although the combined
effects of vitamin D deﬁciency and poly(I:C) have not yet been
investigated in the brain, the effects of another widely used
inﬂammatory agent, lipopolysaccharide has. Lipopolysac-
charide preferentially targets the Toll-4 receptor to elicit its
inﬂammatory cascade and vitamin D is known to directly
antagonize this receptor.
129 Accordingly, the co-administra-
tion of 1,25(OH)2D3 with this inﬂammatory agent in rat
hippocampus leads to a recruitment of macrophages, a
reduction in nitric oxide synthesis and preservation of
hippocampal neuronal number.
130 Studies in the developing
brain examining whether the presence or absence of this
vitamin will accordingly suppress or enhance outcomes
mediated by inﬂammatory cytokines released by either
poly(I:C) or lipopolysaccharide are now required.
Conclusions
Conceptually, the research community has moved on from
considering schizophrenia the result of some static brain
lesion whereby a single pathological process is responsible
for the diverse symptomology observed. We now know that
the mature brain is neither static in regards to cell number
(neurogenesis) nor synaptic remodelling (experience-
mediated plasticity). These factors are likely to be even more
prescient in development. Longitudinal studies in adolescents
at high risk of developing schizophrenia tend to indicate that
any anatomical brain alterations occur before symptoms, are
progressive and perhaps the result of enhanced endogenous
processes rather than due to any external effect.
131 The
ethical and temporal demands make studying the aetiology of
schizophrenia in patients an incredibly difﬁcult undertaking.
Therefore, as researchers we turn to animal models in an
attempt to address neurobiological causality.
The two models we have focussed on here are based on
plausible risk factor epidemiology for schizophrenia and have
provided convergent evidence for a common mechanism that
can integrate the two major hypotheses of schizophrenia to
date, namely, that it is a neurodevelopmental disorder and
that abnormalities in DA signalling are central. We speculate
that early alterations in the trajectory of DA neuron develop-
ment may also operate in other developmental models for this
disorder.
132 Given the common phenotype of DA dysfunction
inmostofthesemodelsitissomewhatperplexingthatauthors
rarely, if ever, examine DA-related factors in the developing
brain. On the basis of the data presented here, we propose
that schizophrenia may be a disorder of abnormal DA
ontogeny whereby multiple environmental factors subtly alter
the trajectory of DA neuron birth, positioning and connectivity,
in short, the ontogeny of DA neurons. How these early
alterations can create the structural brain changes that are
believed to be responsible for abnormal DA-mediated
behaviours is now a key focus for our research. It is our hope
that these recent ﬁndings in both the DVD-deﬁciency and MIA
models may prompt other groups to re-investigate dopami-
nergic systems earlier during development than previously
considered in an attempt to verify whether early alterations in
DA ontogeny represent a shared aetiological pathway in
animal models of schizophrenia.
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